Diagnostic platform FluoretiQ completes £1.1 million funding round

Fluoretiq founder Neciah Dorh

Bristol-based diagnostic platform start-up FluoretiQ has completed a £1.1 million pre-series A investment.

The company is developing Nanoplex, a 15-minute proprietary diagnostic platform for bacterial infections.

The round was led by early-stage life science investors, Deepbridge Capital LLP, with significant participation from MAINStream, OION, SAIC and existing investors.

FluoretiQ is developing a family of antibiotic stewardship products that identify a true and correct need for antibiotic prescription.

Nanoplex provides laboratory-quality results, 200 times faster than laboratory analysis, helping clinicians meet their antibiotic stewardship targets.

FluoretiQ’s products will be an important tool in the wake of reports showing that Antimicrobial Resistance (AMR) is growing faster than expected.

FluoretiQ CEO Dr Neciah Dorh said: “Recent headlines in the Lancet highlight the need for urgent action to get solutions to preserve the efficacy of current and future antibiotics.

“These funds will enable us to build cutting-edge, rapid diagnostic products that enable true antibiotic stewardship. We’re so fortunate to have a growing list of committed and visionary investors.”

The investment will enable the team to produce trial units of their first Nanoplex product – a 15-minute Urinary Tract Infection diagnostic device.

Dr Savvas Neophytou, partner & head of life sciences at Deepbridge Capital LLP, said: “FluoretiQ perfectly represents the type of highly innovative and growth-focused companies Deepbridge Capital is committed to supporting within the sector-specific Deepbridge Life Sciences EIS fund; a great example of the importance of the Enterprise Investment Scheme,”

“Neciah Dorh has built a great team, eager to take on the significant challenge this market demands, and we are pleased to be working with them on this next exciting stage of their journey.”

Fellow Angel investor, entrepreneur and medical doctor Leonid Shapiro said: “I was impressed with both FlouretiQ’s innovation in bacterial detection and their quest to solve a much-needed problem in managing urinary infections in our nation’s elderly.”